NASDAQ ALDX Lawsuit Alert Investors who lost over 100,000 with shares of Aldeyra Therapeutics, Inc. should contact the Shareholders Foundation
| ALDX Stock | USD 5.01 0.36 6.70% |
Slightly above 61% of Aldeyra's investor base is looking to short. The analysis of the overall investor sentiment regarding Aldeyra suggests that many traders are alarmed. Aldeyra's investing sentiment can be driven by a variety of factors including economic data, Aldeyra's earnings reports, geopolitical events, and overall market trends.
Aldeyra |
SAN DIEGO, Aug. 15, 2023 The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Aldeyra Therapeutics, Inc. shares in effort to recover losses.
Read at benzinga.com
 |
Aldeyra Fundamental Analysis
We analyze Aldeyra's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aldeyra using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aldeyra based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Aldeyra is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Aldeyra Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aldeyra stock to make a market-neutral strategy. Peer analysis of Aldeyra could also be used in its relative valuation, which is a method of valuing Aldeyra by comparing valuation metrics with similar companies.
Peers
Aldeyra Related Equities
| INZY | Inozyme Pharma | 0.68 | ||||
| ETON | Eton Pharmaceuticals | 0.41 | ||||
| ARDX | Ardelyx | 1.50 | ||||
| TERN | Terns Pharmaceuticals | 1.64 | ||||
| BPMC | Blueprint Medicines | 2.00 | ||||
| TARS | Tarsus Pharmaceuticals | 2.03 | ||||
| ETNB | 89bio | 2.36 | ||||
| CGEM | Cullinan Oncology | 2.56 | ||||
| DAWN | Day One | 2.66 | ||||
| IBRX | Immunitybio | 3.49 | ||||
| HOOK | Hookipa Pharma | 3.60 | ||||
| TVTX | Travere Therapeutics | 4.12 | ||||
| BLRX | BioLineRx | 4.17 | ||||
| MCRB | Seres Therapeutics | 4.44 | ||||
| LYRA | Lyra Therapeutics | 4.76 | ||||
| PHAT | Phathom Pharmaceuticals | 4.88 | ||||
| VRDN | Viridian Therapeutics | 5.22 | ||||
| GPCR | Structure Therapeutics | 7.42 | ||||
| LXRX | Lexicon Pharmaceuticals | 7.87 | ||||
| XFOR | X4 Pharmaceuticals | 21.05 |
Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.